Germany Suspends Takeda Diabetes Drug Actos

Law360, New York (June 10, 2011, 5:42 PM EDT) -- German health regulators on Friday advised doctors to halt new prescriptions of Takeda Pharmaceutical Co. Ltd.'s diabetes drug Actos in light of study results suggesting the medication could heighten the risk of bladder cancer.

The announcement from Germany's Federal Institute for Drugs and Medical Devices follows France's decision Thursday to suspend use of drugs containing pioglitazone, based on testing in that country showing increased bladder cancer risks.

That suspension includes Takeda's Competact-brand drug, which is a combination of pioglitazone and metformin. Both Actos and Competact are...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.